SCHEMBL3548205

SCHEMBL3548205

C#CCOc1ccc(C(=S)N2CCC2C(=O)OC)cc1C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 2/20 0.40
SCN9A Q15858 2/20 0.36
SSTR4 P31391 2/20 0.36
ALDH1A1 P00352 5/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
RBP4 P02753 3/20 0.35
TTR P02766 1/20 0.35
PDE4B Q07343 1/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
SSTR1 P30872 1/20 0.34
CYP2B6 P20813 1/20 0.34
POLB P06746 1/20 0.34
EPHX2 P34913 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3548207 1.00 PDK2 (0.40) PDK2SCN9ASSTR4ALDH1A1PKM
SCHEMBL3548717 0.89 SCN9A (0.37) SCN9ASSTR4ALDH1A1PKMRBP4
SCHEMBL3548720 0.89 SCN9A (0.37) SCN9ASSTR4ALDH1A1PKMRBP4
SCHEMBL3550931 0.88 PDK2 (0.42) PDK2SCN9ASSTR4ALDH1A1PKM
SCHEMBL3544340 0.88 SMN1; SMN2 (0.43) PDK2SCN9AALDH1A1HPGDRXRA
SCHEMBL3544342 0.88 SMN1; SMN2 (0.43) PDK2SCN9AALDH1A1HPGDRXRA
SCHEMBL3550927 0.88 PDK2 (0.42) PDK2SCN9ASSTR4ALDH1A1PKM
SCHEMBL3546552 0.87 THRA (0.42) PDK2SCN9ASSTR4ALDH1A1HPGD
SCHEMBL3546548 0.87 THRA (0.42) PDK2SCN9ASSTR4ALDH1A1HPGD
SCHEMBL3546497 0.86 PDK2 (0.45) PDK2ALDH1A1PKMHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE PDK2 2445/4885SCN9A 4080/4885SSTR4 3014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.